Portal de Periódicos da CAPES

Spirometric Maneuvers And Inhaled Salbutamol Do Not Affect Exhaled Nitric Oxide Measurements

2009; Elsevier BV; Volume: 123; Issue: 2 Linguagem: Inglês

10.1016/j.jaci.2008.12.032

1097-6825

Teresa Garriga‐Baraut, Moisés Labrador‐Horrillo, Olga Luengo, Mar Guilarte, Victòria Cardona,

Chronic Obstructive Pulmonary Disease (COPD) Research

RATIONALE: Exhaled nitric oxide (ENO) is used as a marker of airway inflammation. Factors such as spirometric maneuvers, beta2-agonists or tobacco smoking have been postulated to affect ENO measurements. Recommended guidelines about measurement techniques have been published based on expert opinions. Nevertheless, there is no strong clinical evidence on many aspects because they have not been supported by research data. So, the aim of this study was to evaluate the influence of perfoming a spirometry or recieving inhaled salbutamol on ENO readings.METHODS: 60 patients with allergic asthma and/or rhinoconjunctivitis were included, 21 males and 39 females with a mean age of 36,1 ± 14,9. ENO measurements were performed with a Niox Mino® electrochemical device. In 44 patients ENO was measured before and after performing spirometric maneuvers and in 16 patients before and fifteen minutes after performing spirometric maneuvers plus two puffs of salbutamol (100 microgram/puff).RESULTS: There were no significant differences in mean ENO levels before and after spirometric maneuvers (mean 49,3 ± 41,6 vs 49,8 ± 40,7 parts per billion [ppb]; p = 0.541) or before and after spirometric maneuvers plus two puffs of inhaled salbutamol (median 53,5 [interquartile range, IQR 20,8-127,8] vs 57,5 [IQR 25,5-119] ppb; p = 0,795).CONCLUSIONS: Levels of ENO are not significantly affected by spirometric maneuvers or salbutamol inhalation. RATIONALE: Exhaled nitric oxide (ENO) is used as a marker of airway inflammation. Factors such as spirometric maneuvers, beta2-agonists or tobacco smoking have been postulated to affect ENO measurements. Recommended guidelines about measurement techniques have been published based on expert opinions. Nevertheless, there is no strong clinical evidence on many aspects because they have not been supported by research data. So, the aim of this study was to evaluate the influence of perfoming a spirometry or recieving inhaled salbutamol on ENO readings. METHODS: 60 patients with allergic asthma and/or rhinoconjunctivitis were included, 21 males and 39 females with a mean age of 36,1 ± 14,9. ENO measurements were performed with a Niox Mino® electrochemical device. In 44 patients ENO was measured before and after performing spirometric maneuvers and in 16 patients before and fifteen minutes after performing spirometric maneuvers plus two puffs of salbutamol (100 microgram/puff). RESULTS: There were no significant differences in mean ENO levels before and after spirometric maneuvers (mean 49,3 ± 41,6 vs 49,8 ± 40,7 parts per billion [ppb]; p = 0.541) or before and after spirometric maneuvers plus two puffs of inhaled salbutamol (median 53,5 [interquartile range, IQR 20,8-127,8] vs 57,5 [IQR 25,5-119] ppb; p = 0,795). CONCLUSIONS: Levels of ENO are not significantly affected by spirometric maneuvers or salbutamol inhalation.